Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TAF1 | P21675 | 1/20 | 0.45 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28316145 | 0.87 | ALDH1A1 (0.44) | LMNAUSP30CCR5PDK2ALDH1A1 | |
| SCHEMBL3329900 | 0.84 | CCR5 (0.55) | MCHR1USP30CCR5HRH3JAK2 | |
| SCHEMBL25498560 | 0.83 | LMNA (0.65) | MCHR1LMNABRD4TAF1CECR2 | |
| SCHEMBL12082859 | 0.83 | PDK2 (0.61) | MCHR1LMNABRD4TAF1CECR2 | |
| SCHEMBL23387934 | 0.82 | LMNA (0.43) | MCHR1LMNABRD4TAF1CECR2 | |
| SCHEMBL1164100 | 0.82 | MCHR1 (0.50) | MCHR1LMNABRD4TAF1CECR2 | |
| SCHEMBL94337 | 0.82 | MCHR1 (0.50) | MCHR1LMNABRD4TAF1CECR2 | |
| SCHEMBL16553814 | 0.82 | HTR2A (0.54) | MCHR1LMNABRD4TAF1CECR2 | |
| SCHEMBL16578852 | 0.81 | SMO (0.53) | MCHR1LMNAUSP30CCR5PDK2 | |
| SCHEMBL3039614 | 0.80 | SLC6A4 (0.43) | MCHR1USP30PDK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | MCHR1 389/4885LMNA 4102/4885BRD4 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.